Thymosin α1: A different thymic peptide — and a large sepsis trial that did not move mortality

If your last Journal stop was TB-500 and Thymosin β4, the word thymosin still needs unpacking. Thymosin α1 is not a shorter motif of that actin story. It is a different molecule, from a different research program, with a different clinical paper trail.

Literature, not lore.

Chemically, mature Thymosin α1 is a 28-amino-acid N-acetylated peptide originally isolated from thymus. The synthetic drug substance is usually called thymalfasin. Internationally it has been marketed as Zadaxin and related brands for chronic hepatitis B and as an immune adjuvant in various jurisdictions. It is not an FDA-approved drug product in the United States. That split — labeled product abroad, research conversation at home — is the same habit this Journal already uses for related-but-not-identical product worlds.

Not the actin-binding thymosin

Thymosin β4 is a 43-residue G-actin sequestering protein with a rodent wound literature. Catalog TB-500 is typically a short actin-binding motif from that protein. Thymosin α1 sits elsewhere: dendritic-cell and T-cell immunomodulation, Toll-like receptor–adjacent framing in reviews, and clinical programs that asked about infection, vaccine response, and critical illness — not dermal re-epithelialization. Same Greek letter family in the common name. Different sequence. Different experiment.

What the sepsis trials actually measured

Smaller controlled studies and earlier meta-analyses suggested thymosin α1 might lower short-term mortality in sepsis, often with soft methods and modest samples. ETASS (2013) enrolled 361 adults with severe sepsis across six Chinese hospitals: 28-day all-cause mortality was 26.0% with Tα1 versus 35.0% in controls (relative risk 0.74, 95% CI 0.54–1.02) — a marginal signal that invited a larger test, not a settled practice guideline.

TESTS (published 2025 in The BMJ) was that larger test: a multicentre, double-blind, placebo-controlled phase 3 trial. Of 1,106 enrolled adults with sepsis, 1,089 entered the modified intention-to-treat analysis. Twenty-eight-day all-cause mortality was 23.4% with thymosin α1 and 24.1% with placebo (hazard ratio 0.97, 95% CI 0.76–1.24). Secondary and safety outcomes did not differ in a statistically clear way. Prespecified subgroup glances are hypothesis generators, not a rescue of the primary null.

A bigger, cleaner trial can erase a hopeful meta-analysis. That is how evidence is supposed to work.

A 2025 systematic review and meta-analysis still pooled a mortality reduction across eleven randomized trials, then showed the signal weakening or vanishing in high-quality and multicenter subgroups. Trial-sequential analysis said the information size is still thin. Pooling small trials is not the same shelf as one adequately powered phase 3.

Regulatory context without the sales pitch

FDA materials for the December 4, 2024 Pharmacy Compounding Advisory Committee meeting reviewed thymosin alpha-1–related bulk substances after a 503A nomination that was later withdrawn. The Agency put the question on a public calendar. That is regulatory context, not approval of a labeled U.S. product, and not a ban on laboratory research on the peptide.